Raymond A. Miller and N. Nicole Endejann, Pittsburgh attorneys in Pepper Hamilton’s Intellectual Property Practice and Life Sciences Practice, and Tom Petzinger, Executive Vice President of Business Development and Public Affairs of Knopp Neurosciences Inc., identify the intellectual property and regulatory exclusivity strategies necessary for emerging life science companies to secure investments, strategic partnerships or licenses with third parties. In addition to reviewing critical IP strategies, this podcast discusses the recent Knopp – Biogen Idec transaction, in which Pepper served as IP counsel. Knopp developed the drug, dexpramipexole, for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and potentially other indications. In August, Biogen Idec and Knopp Neurosciences entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize the drug.
Email email@example.com to subscribe to Pepper Hamilton’s IP Alerts and Updates.
(Running Time: 26:28)
TrackBack URL for this entry:
Listed below are links to weblogs that reference Integration of IP and Regulatory Exclusivity Strategies for Emerging Life Science Companies: